Pharma
Sackler Family and Purdue Pharma Agree to Enhanced $7.4 Billion Opioid Settlement
Sackler family, Purdue Pharma, opioid settlement, $7.4 billion, multistate agreement, opioid crisis, addiction treatment, recovery programs
Biotech IPOs Kick Off 2025: Ascentage Pharma Raises $126M, Aardvark Therapeutics Files for IPO
Biotech IPOs, Ascentage Pharma, Aardvark Therapeutics, Cancer Treatment, Obesity Treatment, Pharmaceutical Industry
Leo Pharma Acquires EU Rights to Loqtorzi, Boosting Marketing Efforts for PD-1 Inhibitor
Loqtorzi, PD-1 Inhibitor, Nasopharyngeal Carcinoma, EU Rights, Leo Pharma, Junshi Biosciences, Marketing Efforts
RyCarma Therapeutics Unveils New Leadership and Company Name, Expands Focus on Heart Failure Treatment
RyCarma Therapeutics, ARMGO Pharma, ryanodine receptor, Rycals, heart failure, cardiovascular diseases, skeletal muscle diseases, biotech company, new leadership, company name change.
Key Takeaways from #JPM25: Strategic Partnerships and Acquisitions Dominate the JP Morgan Healthcare Conference
JP Morgan Healthcare Conference, #JPM25, biopharma industry, acquisitions, partnerships, Eli Lilly, Zealand Pharma, GSK, Scorpion Therapeutics
Gilead Sciences Expands into Inflammatory Diseases with $1.7 Billion Collaboration with LEO Pharma
Gilead Sciences, LEO Pharma, STAT6 inhibitors, inflammatory diseases, eczema, asthma, COPD, biotech deal, JPM25
Gilead and LEO Pharma Collaborate on STAT6 Inflammatory Disease Programmes
Gilead Sciences, LEO Pharma, STAT6, inflammatory diseases, partnership, oral formulations, dermatology
Revival of Dormant Antipsychotic Class: LB Pharma’s Phase II Success with LB-102
LB Pharma, LB-102, Antipsychotic drugs, Schizophrenia treatment, Phase II clinical trials, Benzamide antipsychotics
Adragos Pharma Expands Global Reach with Acquisition of Swiss CDMO Baccinex
Adragos Pharma, Baccinex, CDMO, aseptic fill-finish, sterile drug production, pharmaceutical manufacturing
Enveda Secures $130 Million in Funding for Innovative Therapies in Inflammation, Obesity, and Beyond
Enveda, Microsoft-backed, $130M funding, Inflammation & Immunology (I&I), obesity, biotech, pharma, drug development